Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Alkermes ( (ALKS) ) is now available.
On September 12, 2025, Alkermes plc announced the appointment of Joshua Reed as Senior Vice President and Chief Financial Officer, effective September 15, 2025. Mr. Reed, who brings over 30 years of financial leadership experience in the biotechnology and pharmaceutical sectors, will assume the role of the company’s principal financial officer. His appointment is expected to strengthen Alkermes’ financial strategy and support its long-term growth and innovation goals, as emphasized by CEO Richard Pops.
The most recent analyst rating on (ALKS) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes’ strong financial performance and positive earnings call are the most significant factors driving the score. The company’s robust cash position and successful clinical trials further enhance its outlook. Technical analysis and valuation are supportive but less impactful.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. The company offers proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, and is developing clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also operates a corporate office and research center in Massachusetts and a manufacturing facility in Ohio.
Average Trading Volume: 1,953,485
Technical Sentiment Signal: Hold
Current Market Cap: $4.57B
For detailed information about ALKS stock, go to TipRanks’ Stock Analysis page.